Eye Health Product Manufacturing OTC in European Union: Market Size, Businesses & Forecast 2026

The over-the-counter (OTC) eye health product manufacturing industry in the European Union encompasses the formulation, production, and packaging of non-prescription eye care solutions, primarily including artificial tears, lubricating eye drops, and ocular hygiene products. The industry is steering towards advanced preservative-free formulations and multi-dose delivery systems to accommodate rising consumer demand for safer self-care regimens. While comprehensive, separate statistical indicators isolated exclusively for the OTC ocular subsegment are not independently aggregated by public bodies, the broader manufacturing of pharmaceutical preparations in the EU (NACE 21.20) provides an oper

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Eye Health Product Manufacturing OTC in European Union industry cover?

The industry comprises the manufacturing of non-prescription, over-the-counter preparations applied topically to the eye or used for ocular maintenance. These products are manufactured under strict sterile conditions to treat minor ocular ailments such as dry eye syndrome, seasonal allergic conjunctivitis, and general eye fatigue. The scope explicitly covers artificial tears, wash solutions, and decongestant drops, while excluding prescription ophthalmic pharmaceuticals and retail-level optical goods.

• •Primary products include lubricating drops, redness relievers, and lid hygiene wipes.
• •Production requires cleanroom environments meeting European Good Manufacturing Practice (GMP) standards.
• •Products are distinct from prescription-only anti-VEGF agents or glaucoma therapeutics.

Who operates in the industry and how is it structured?

The market structure consists of a mix of specialized ophthalmic healthcare companies and broad-based international pharmaceutical manufacturers operating local production facilities within the European Union. These operators run highly automated, sterilized production lines that yield both branded proprietary lines and generic private-label supplies for retail pharmacies. Distribution is strictly controlled through standardized European logistical chains ensuring product stability.

• •Manufacturing is dominated by established multinational entities with specialized European sites.
• •Production includes both high-viscosity gels and low-viscosity aqueous drops.
• •Contract Manufacturing Organizations (CMOs) provide localized manufacturing options across the EU.

What drives demand in the industry?

Demand is heavily driven by demographic factors and modern lifestyle alterations that increase the prevalence of environmental dry eye symptoms. An expanding aging population across Western and Eastern Europe naturally accelerates the incidence of tear film instability and chronic ocular discomfort. Furthermore, the ubiquity of digital displays in workplace and personal environments exacerbates digital eye strain among younger demographics.

• •The European Commission reported that 21.6% of the EU population was aged 65 or older in 2024.
• •Prolonged daily screen time and digital device usage significantly increase self-medication trends.
• •Growing consumer preference for self-care practices drives OTC channel growth over clinical consultations.

Who are the notable companies in the industry?

The competitive landscape features intense competition among global eye care pioneers and large public pharmaceutical companies with extensive manufacturing infrastructures in Europe. Manufacturers continuously compete on packaging innovations, such as patented multi-dose preservative-free (MDPF) bottles, to capture market share. Brands aggressively market their specialized formulations directly to consumers while maintaining tight alignment with European pharmacy networks.

• •Alcon Inc. maintains a prominent position, actively expanding its advanced preservative-free portfolios.
• •Bausch + Lomb Corporation holds a significant footprint, bolstered by its strategic acquisition of the Blink OTC line.
• •AbbVie Inc. operates as a key competitor following its legacy acquisition of Allergan's leading Refresh brand portfolio.
• •Théa Laboratories (Laboratoires Théa), a major European independent ophthalmic group, pioneers preservative-free technology.

What are the recent trends and outlook?

Recent manufacturing trends emphasize the complete phase-out of traditional preservatives like benzalkonium chloride due to long-term corneal tolerance concerns. Manufacturers are heavily investing in specialized valves and airless bottle designs that keep solutions sterile without chemical preservatives after opening. The outlook remains favorable as companies integrate eco-friendly packaging materials and streamlined multi-dose dispensing formats.

• •A strong shift toward preservative-free formulations dominates new product development lines.
• •Advanced multi-dose vials with specialized filtration mechanisms are replacing single-use pipettes.
• •Integration of artificial intelligence in early diagnostic screening, such as the EU-funded I-SCREEN project, indirectly highlights long-term eye health awareness.

How is the industry regulated?

Manufacturing and commercialization are strictly governed by European Union health regulations that classify certain eye drops depending on their active mechanism. Products utilizing chemical active ingredients are evaluated as medicinal products under national competent authorities and the European Medicines Agency (EMA). Conversely, many lubricating solutions have historically been regulated under the EU Medical Device Regulation (MDR) as ophthalmic devices.

• •Compliance with EU Regulation 2017/745 (Medical Device Regulation) imposes stringent clinical evidence rules.
• •Facilities must strictly adhere to EudraLex Volume 4 guidelines for medicinal products for human use.
• •The European Council of Optometry and Optics (ECOO) monitors broader systemic shifts in patient eye care standards.

Government, statistical and trade sources used for this Claight analysis.

• Eurostat Structural Business Statistics 2024 ·
• European Commission Demographic Reports 2024 ·
• European Medicines Agency (EMA) ·
• European Council of Optometry and Optics (ECOO) 2025